eXoZymes Inc (NASDAQ: EXOZ) is a biotechnology company that develops cell-free enzymatic biomanufacturing technology, called exozymes, to produce small-molecule chemicals outside of living cellular environments. Revenue has come primarily from government and private grants rather than product sales: cumulative grant receipts totaled $17,697,378 from inception through December 31, 2025, including $4,058,367 awarded in 2025 and $1,048,302 awarded in 2024. The company completed its IPO on November 11, 2024, and trades on Nasdaq under the symbol EXOZ. eXoZymes operates from approximately 10,000 square feet of laboratory and R&D space in Monrovia, California. The company carries a going-concern qualification as of the 10-K filed March 30, 2026, with recurring operating losses, negative operating cash flows, and an accumulated deficit. Near-term commercial focus is on low-volume, high-value natural products and derivatives intended as active ingredients in nutraceuticals, with longer-term ambitions in pharmaceutical, specialty chemical, and biofuel markets.

Revenue model

Grant-funded at present. Cumulative grants of $17,697,378 received from inception through December 31, 2025, sourced from U.S. government programs including a ~$1,000,000 Department of Defense BioMADE cost-share grant (October 2024) and a $283,805 NIH BioClick grant (March 2025). Additional revenue from a concurrent private placement of 93,750 warrants at $0.125 each, generating gross proceeds of approximately $11,719 at closing of the IPO. No commercial product revenue is disclosed in the filing excerpts.

Products and services

Exozyme technology platform: cell-free enzymatic pathways that conduct multi-step biochemical reactions outside living cells to produce natural products and small-molecule chemicals. Near-term product focus is on nutraceutical active ingredients. The platform is also being applied to isobutanol biomanufacturing (funded by the DOD BioMADE grant) and to a cell-free high-throughput platform for enzymatic group transfer reactions (funded by the NIH BioClick grant).

Customers and end markets

No commercial customers disclosed in the filing excerpts. Target end markets identified in the 10-K (filed 2026-03-30) are nutraceuticals (near-term), pharmaceuticals (medium-term), and specialty chemicals and biofuels (long-term).

Value-chain role

Technology platform developer and early-stage manufacturer. eXoZymes positions its exozyme platform as a biomanufacturing alternative to both traditional chemical synthesis and cell-based synthetic biology, targeting higher titers, yields, and purity by removing enzymatic reactions from cellular constraints. The company conducts enzyme engineering, exozyme pathway design, and pilot-scale R&D at its Monrovia, California facility.

Geographic exposure

Operations headquartered in Monrovia, California. No international operations or geographic revenue mix disclosed in the filing excerpts.

Competitors

Debut Biotech, Solugen Inc., Codexis Inc., Allozymes Pte Ltd., Enzymit Ltd., Zymtronix Catalytic Systems Inc., Arzeda Corp., Quantumzyme LLP, Valero Energy Corporation, ADM Corporation, Cargill Company, Gevo Inc., Butamax Advanced Biofuels LLC

Source: SEC 10-K, filed 2026-03-30

Industry: Biological Products, (No Diagnostic Substances)